Lv12
20 积分 2024-07-05 加入
Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase 3 DESTINY-Breast04 trial
3小时前
待确认
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
5小时前
已完结
Targeting drug resistance in breast cancer: a dual-perspective landscape analysis of PROTACs from bench to bedside
1天前
已完结
Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysis
1天前
已完结
Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study
1天前
已完结
Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer
1天前
已完结
皖公网安备34019202002308
